Avtor/Urednik		Janež, Andrej
Naslov		Mesto tiazolidindionov v zdravljenju sladkorne bolezni tipa 2
Prevedeni naslov		The role of thiazolidinediones in the treatment of type 2 diabetes mellitus
Tip		članek
Vir		In: Židanik S, Tušek-Bunc K, editors. Medicinsko tehnični pripomočki. Zbornik 3. mariborski kongres družinske medicine; 2004 nov 26-27; Maribor. Ljubljana: Združenje zdravnikov družinske medicine SZD,
Leto izdaje		2004
Obseg		str. 24-5
Jezik		slo
Abstrakt		Rosiglitazone is a member of the thiazolidinediones, a novel class of oral antidiabetic agents that improves glycemic control by reducing insulin resistance and reducing hepatic glucose output. Rosiglitazone binds and activates a nuclear receptor PPARgamma, which stimulates glucose transport in skeletal muscles and adipocytes. Numerous clinical studies wuh rosiglitazone have showed that these agents are effective at improving glycaemic control-with significant reduction in fasting and postprandial glucose and glycosylated haemoglobin HbA1c. A growing body of evidence also suggests that rosiglitazone have a positive impact on risk factors associated with an increased risk of cardiovascular disease, such as dyslipidaemia, abdominal obesity, hypertension, microalbuminuria and fibrinoloysis.
Deskriptorji		DIABETES MELLITUS, NON-INSULIN-DEPENDENT THIAZOLES METFORMIN